FELBATOL (felbamate) by Viatris (2) is mechanism of action the mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Approved for epilepsy, anemia. First approved in 1993.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
FELBATOL (felbamate) is an oral anti-epileptic agent approved in 1993 as a suspension formulation for treating epilepsy and anemia. The mechanism of action is not fully understood, but felbamate demonstrates anticonvulsant activity through multiple pathways including antagonism at the strychnine-insensitive glycine recognition site of the NMDA receptor and weak effects on GABA and benzodiazepine receptors. It is positioned as a broad-spectrum anticonvulsant capable of reducing seizure spread and increasing seizure threshold across multiple seizure types.
Mechanism of Action The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Felbamate is effective in mice and rats in the maximal…
Anti-epileptic Agent
Worked on FELBATOL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCurrently zero job openings are linked to FELBATOL, reflecting the product's mature, declining lifecycle stage with minimal commercial investment. Roles typically associated with legacy anti-epileptic agents include brand management focused on market defense, field team support for niche patient populations, and medical liaison activities for neurologists, though limited headcount expansion is expected as the product approaches generic competition and faces declining utilization.